Agluna® is a novel, patented surface modification technology applied to medical devices manufactured from several metals including titanium and its various alloys. The goal of the technology is to reduce infection rates following surgical procedures. Medical device materials are susceptible to rapid colonisation by bacteria, which then surround themselves with a plaque or biofilm as protection against the body’s immune defences. Implants treated with Agluna® technology have been shown to remain clear of such biofilm formation, thereby reducing the incidence of serious post-operative, device-related infection.
Philip Agg, Chief Executive of Accentus Medical, said: “The award of a CE mark to a device incorporating Agluna® is an important indicator of the broader potential of the technology and we are pleased to have worked closely with Stanmore Implants to achieve this major step in our development. Accentus Medical is now poised to work with Zimmer, Inc., a global market leader in musculoskeletal care, our exclusive partner in the field of joint replacement implants, to further develop this highly promising technology for the global hip and knee market. We have also initiated studies, in disciplines such as cardiovascular medicine and neurosurgery, aimed at placing Agluna® at the heart of infection control beyond the orthopaedic sector.”
Martin Pickford, Senior Vice-President of Business Development for Accentus Medical, said: “Infection following implant surgery can be challenging, costly and time consuming to treat. Prevention of infection at the outset is a highly attractive solution for both patents and clinicians. Data generated from clinical usage of custom made tumour replacement implants at two major UK orthopaedic oncology centres since 2006, has demonstrated how the Agluna® technology can help in realising this solution.”
Brian Steer, Executive Chairman of Stanmore, said: “With infection being a major burden on the healthcare system and often leading to avoidable amputations, we are delighted to secure approval for our silver treated METS system. There is increasing evidence to support silver’s anti-microbial properties and incorporating it into our METS system puts Stanmore in a very strong competitive position. We expect to see demand rapidly increase and we look forward to working with doctors around the world to help improve the lives of patients.”
For further information, please contact:
Lynne Trowbridge, Tim Watson
Accentus Medical
T: +44 (0)20 7866 7861
Email: AccentusMedical@collegehill.com
Ben Atwell, Stephanie Cuthbert (Financial Dynamics)
Stanmore Implants Worldwide
T : +44 (0)20 7831 3113
About Accentus Medical
Accentus Medical is a leading medical technology company that combines a long history of expertise in surface coating and modification technologies with dedicated research and development of new technologies for the medical device industry. With roots in the United Kingdom Atomic Energy Authority, and based at the historic Harwell Oxford campus, Accentus Medical has provided expertise in surface technologies to the orthopaedic device industry since the 1970s, serving major orthopaedic and medical device manufacturers worldwide.
The company works closely with industry partners to develop new surface technologies that address unmet market needs, and is renowned for its experienced staff and track record for responsive, high quality service. The services offered include hydroxyapatite and metal alloy coatings (known as Acusure®) using a plasma spray process at Accentus Medical’s ISO 13485:2003 and ISO 9000:2000 accredited facility. Accentus Medical is also very well known for the medical device testing programmes offered by its in-house test laboratories. Manufacturers have been utilising test results provided by the company for many years as part of device homologation files all over the world.
For further information, please visit: www.accentus-medical.com
About Stanmore Implants Worldwide
Stanmore Implants Worldwide is an innovative orthopaedic business focused on the design and manufacture of both bespoke and modular implants for limb sparing and complex primary and revision joint replacement.
Stanmore designs, manufactures and markets a custom implant service alongside a portfolio of orthopaedic implants for limb salvage and complex joint replacement, and is known for creating some of the world's most successful implants.
Stanmore acquired its robotic bone preparation technology through the acquisition of Acrobot, a medical devices company specialising in computer assisted orthopaedic surgery in August 2010.
For further information, please visit: www.stanmoreimplants.com
